Breaking News Instant updates and real-time market news.

ADMP

Adamis Pharmaceuticals

$3.50

(0.00%)

, TD

Toronto-Dominion

$61.35

(0.00%)

09:40
09/25/18
09/25
09:40
09/25/18
09:40

Unusually active option classes on open September 25th

Unusual total active option classes on open include: Adamis Pharmaceuticals (ADMP), Toronto Dominion Bank (TD), TakeTwo Interactive Software (TTWO), BP (BP), Barrick Gold (ABX), Market Vectors Oil Services (OIH), Morgan Stanley (MS), CenturyLink (CTL), Pandora (P), and Square (SQ).

ADMP

Adamis Pharmaceuticals

$3.50

(0.00%)

TD

Toronto-Dominion

$61.35

(0.00%)

TTWO

Take-Two

$134.87

(0.00%)

BP

BP

$45.23

(0.00%)

ABX

Symbol changed to GOLD

$11.03

(0.00%)

OIH

Oil Services Holders Trust

$25.30

(0.00%)

MS

Morgan Stanley

$48.56

(0.00%)

CTL

CenturyLink

$22.90

(0.00%)

P

Pandora

$8.98

(0.00%)

SQ

Square

$86.06

(0.00%)

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 02

    Oct

  • 11

    Oct

  • 13

    Nov

  • 26

    Nov

  • 27

    Nov

ADMP Adamis Pharmaceuticals
$3.50

(0.00%)

08/23/18
HCWC
08/23/18
NO CHANGE
Target $7
HCWC
Buy
Adamis selloff on generic EpiPen a buying opportunity, says H.C. Wainwright
Recent weakness in shares of Adamis Pharmaceuticals (ADMP) appears related to news that Teva (TEVA) has received approval to launch a generic version of Mylan's (MYL) EpiPen, H.C. Wainwright analyst Jason Kolbert tells investors in a research note. Sandoz, Adamis' partner, is well aware of Teva's initiatives and remains committed to the launch of Adamis' Symjepi, the analyst adds, As such, he views the recent pullback in Adamis as a buying opportunity. He lowered his price target for the stock to $7 from $10 and keeps a Buy rating on the name.
07/02/18
MAXM
07/02/18
NO CHANGE
Target $13
MAXM
Buy
Adamis Pharmaceuticals price target raised to $13 from $10 at Maxim
Maxim analyst Jason McCarthy raised his price target on Adamis Pharmaceuticals to $13 and kept his Buy rating after the company announced a commercial partnership for Symjepi in the U.S. The analyst notes that while the upfront payment may be "modest", the company is also retaining its international rights, adding that this partnership represents a "significant inflection point" for Adamis. McCarthy calls for the company to next focus on its pipeline of injection-based and inhalation-based drugs which are moving to the later stages of development.
07/02/18
HCWC
07/02/18
NO CHANGE
Target $10
HCWC
Buy
Adamis price target raised to $10 from $7 at H.C. Wainwright
H.C. Wainwright analyst Jason Kolbert raised his price target for Adamis Pharmaceuticals (ADMP) to $10 after the company announced that Novartis (NVS) division Sandoz division will commercialize Symjepi. While the deal took longer than expected, the terms of a 50:50 split is better than anticipated, Kolbert tells investors in a research note. The analyst sees Sandoz as a "great partner" and reiterates a Buy rating on Adamis.
07/02/18
RILY
07/02/18
NO CHANGE
Target $7.5
RILY
Buy
Adamis price target raised to $7.50 from $6.25 at B. Riley FBR
B. Riley FBR analyst Andrew D'Silva raised his price target for Adamis Pharmaceuticals (ADMP) to $7.50 after the company entered into a strategic partnership with Novartis (NVS) unit Sandoz. The analyst views the agreement as favorable and keeps a Buy rating on Adamis.
TD Toronto-Dominion
$61.35

(0.00%)

10/24/17
MACQ
10/24/17
INITIATION
Target $61
MACQ
Outperform
Toronto-Dominion initiated with an Outperform at Macquarie
Macquarie analyst Mike Rizvanovic initiated Toronto-Dominion with an Outperform and $61 price target.
02/01/18
CIBC
02/01/18
UPGRADE
CIBC
Outperformer
Toronto-Dominion upgraded to Outperformer from Neutral at CIBC
03/02/18
DESJ
03/02/18
UPGRADE
DESJ
Buy
Toronto-Dominion upgraded to Buy from Hold at Desjardins
Desjardins analyst Doug Young upgraded Toronto-Dominion to Buy with a C$84 price target.
05/25/18
BMOC
05/25/18
NO CHANGE
Target $82
BMOC
Outperform
Toronto-Dominion price target raised to $82 from $79 at BMO Capital
BMO Capital analyst Sohrab Movahedi raised his price target on TD Bank to $82 after its Q2 earnings beat, citing strength in the Canadian retail. The analyst notes 17% growth in the segment's P&C banking as well as the 16% rise in Wealth & Insurance. Movahedi adds that TD's core equity tier 1 ratio was a "solid" 11.8%, giving the bank "excess" capital position. The analyst keeps his Outperform rating on TD Bank.
TTWO Take-Two
$134.87

(0.00%)

09/10/18
BNCH
09/10/18
NO CHANGE
Target $156
BNCH
Buy
Benchmark convinced Take-Two's 'Red Dead 2' will greatly exceed forecasts
After meeting with Take-Two's executive team last week, Benchmark analyst Mike Hickey said he remains convinced that the upcoming release of "Red Dead Redemption 2" will greatly exceed consensus forecasts. He reiterate his Buy rating on Take-Two shares with a $156 price target, citing his view of its "potentially enormous near term earnings power."
09/11/18
STFL
09/11/18
NO CHANGE
STFL
Buy
Activision Blizzard added to Stifel Select List, Electronic Arts removed
Stifel analyst Drew Crum, in his annual holiday preview for the video games industry, said he sees the global market ending 2018 up low double-digits in terms of growth, calling the upcoming holiday software line-up the best that has been seen during the current console cycle in terms of the quantity of AAA titles. Crum added Activision Blizzard (ATVI) to the Stifel Select List, based on expectations for a solid holiday, building anticipation ahead of BlizzCon, and further newsflow for the Overwatch League. He also removed Electronic Arts (EA) from the Select List and lowered his price target for EA shares to $140 from $159, as he said pre-sales for "Battlefield V" look "underwhelming." Additionally, Crum raised his price target for Take-Two (TTWO) shares to $144 from $137, citing his growing optimism for "Red Dead Redemption 2" based on his pre-sales analysis. Crum maintains Buy ratings on all three video game makers mentioned.
09/14/18
PIPR
09/14/18
NO CHANGE
PIPR
August NPD video game software sales were flat, says Piper Jaffray
Overall August NPD video game software sales were flat year-over-year, driven by a "solid" launch of Madden NFL '19 from Electronic Arts (EA), the top title for August, Piper Jaffray analyst Michael Olson tells investors in a research note. The analyst views the August NPD data as less relevant for Activision Blizzard (ATVI) Activision and Take-Two (TTWO), given his expectation for greater than 75% of their revenue coming from digital sources, including a launch of Activision's World of Warcraft for PC, which NPD data does not include. Olson keeps an Overweight rating on all three stocks.
09/19/18
KEYB
09/19/18
NO CHANGE
KEYB
Overweight
KeyBanc says buy shares of Take Two, Activision Blizzard into holiday season
KeyBanc analyst Evan Wingren says he remain positives on video games into what should be a strong holiday. In a research note to investors, Wingren says his favorite ways to play the holiday season are Take Two (TTWO) and Activision Blizzard (ATVI) and that he would be buying shares. Though he acknowledges that fundamentals softened in Q2 as competition impacted upside to estimates, he expects fundamentals to improve into 2019, driven by strong games, new content and new growth opportunities. The analyst expects Take Two's Red Dead Redemption 2 to be "one of the biggest releases this holiday," and Activision's Call of Duty: Black Ops III, WoW and Destiny expansions should drive earnings above consensus. He has Overweight ratings on both Take Two and Activision Blizzard, as well as EA (EA).
BP BP
$45.23

(0.00%)

09/05/18
09/05/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Anthem (ANTM) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Zack Sopcak saying he contends that the disruption in the pharmacy benefits management landscape via M&A and government-led drug pricing reform positions Anthem for underappreciated share gain and accelerated profit growth. 2. BP (BP) upgraded to Overweight from Equal Weight at Morgan Stanley. 3. GasLog (GLOG) upgraded to Buy from Hold at DNB Markets. 4. CenterPoint Energy (CNP) upgraded to Overweight from Neutral at JPMorgan with analyst Christopher Turnure saying he sees an "attractive outlook for the proforma company" with 8.2% annual earnings growth through 2021 "under a conservative range of assumptions." 5. PerkinElmer (PKI) upgraded to Equal Weight from Underweight at Barclays with analyst Jack Meehan saying he is more positive on PerkinElmer's near-term growth prospects in Diagnostics due to its recent investments. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/11/18
BREN
09/11/18
INITIATION
BREN
Buy
BP initiated with a Buy at Berenberg
Berenberg analyst Henry Tarr started BP with a Buy rating and 665p price target. The company is starting to grow again, the analyst contends.
09/05/18
MSCO
09/05/18
UPGRADE
MSCO
Overweight
BP upgraded to Overweight from Equal Weight at Morgan Stanley
08/31/18
08/31/18
NO CHANGE

On The Fly: Top five analyst actions
Catch up on today's top five analyst actions with this list compiled by The Fly: 1. BP (BP) and Royal Dutch Shell (RDS.A) were upgraded to Hold from Underperform at Santander. 2. Dollar Tree (DLTR) downgraded to Market Perform from Outperform at Telsey Advisory. 3. Electronic Arts (EA) and Activision Blizzard (ATVI) were downgraded to Neutral from Buy at BofA/Merrill. 4. Gain Capital (GCAP) initiated with a Neutral at JPMorgan. 5. Avaya (AVYA) initiated with a Neutral at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ABX Symbol changed to GOLD
$11.03

(0.00%)

09/25/18
SBSH
09/25/18
UPGRADE
Target $14
SBSH
Buy
Citi sees Randgold deal as win for Barrick, upgrades shares to Buy
Citi analyst Alexander Hacking upgraded Barrick Gold (ABX) to Buy from Neutral and raised his price target for the shares to $14 from $11 saying the company's acquisition of Randgold (GOLD) is a win for Barrick on two levels. One, Barrick management gets an upgrade to the most successful CEO in the sector, which adds "significant credibility" to its turnaround, Hacking tells investors in a research note. And two, the deal solidifies Barrick's capital allocation by removing the acquisition overhang and accelerating assets sales, the analyst adds. He also sees a favorable gold price backdrop with gold "relatively beaten up" at $1,200 per ounce. Hacking coupled the upgrade with a downgrade of Goldcorp (GG) to Neutral from Buy citing the stock's 15% outperformance versus Barrick in the past year.
09/25/18
JPMS
09/25/18
DOWNGRADE
Target $68
JPMS
Neutral
Randgold downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Luke Nelson downgraded Randgold (GOLD) to Neutral and lowered his price target for the shares to $68 from $91. The analyst sees limited chance of a competing bid to emerge following the company's takeover by Barrick Gold (ABX).
09/25/18
TDSI
09/25/18
UPGRADE
TDSI
Buy
Barrick Gold upgraded to Buy from Hold at TD Securities
09/25/18
SBSH
09/25/18
UPGRADE
Target $14
SBSH
Buy
Barrick Gold upgraded to Buy from Neutral at Citi
Citi analyst Alexander Hacking upgraded Barrick Gold (ABX) to Buy and raised his price target for the shares to $14 from $11 following the company's acquisition of Randgold (GOLD).
OIH Oil Services Holders Trust
$25.30

(0.00%)

06/26/18
RBCM
06/26/18
NO CHANGE
Target $35
RBCM
Outperform
Baker Hughes poised to outperform through all phases of cycle, says RBC Capital
RBC Capital analyst Kurt Hallead keeps his Outperform rating and $35 price target on Baker Hughes (BHGE), telling investors that he anticipates an "improved outlook" for its LNG bookings along with "synergy execution within its oilfield service segment, and return of cash to shareholders through buybacks and dividends". The analyst expects Baker Hughes to outperform the broader Oil Services ETF (OIH) through all the phases of the energy cycle as it continues to "bag LNG project awards", benefiting its margins while staying on track for total synergies of $700M this year.
MS Morgan Stanley
$48.56

(0.00%)

09/20/18
RBCM
09/20/18
NO CHANGE
Target $60
RBCM
Outperform
Morgan Stanley EPS ests lowered at RBC Capital on declining advisory fees
RBC Capital analyst Gerard Cassidy kept his Outperform rating and $60 price target on Morgan Stanley but lowered his FY18 EPS view to $4.70 from $4.88 and FY19 view to $5.15 from $5.47. The analyst says his new targets assume advisory fees declining 2% and Equity and Debt Capital Market segments fees decline of 0.9% and 2.3% respectively, even though he sees equity trading revenues rising 5.8%. Cassidy further expects Morgan Stanley's investment management revenue to fall "modestly" on anticipated funds outflow from "money market mutual fund sweeps".
09/25/18
WOLF
09/25/18
INITIATION
Target $61
WOLF
Outperform
Morgan Stanley initiated with an Outperform at Wolfe Research
Wolfe Research analyst Steven Chubak initiated Morgan Stanley with an Outperform and $61 price target.
07/19/18
ARGS
07/19/18
NO CHANGE
Target $62
ARGS
Buy
Morgan Stanley saw strong Q2, recent price weakness 'unwarranted', says Argus
Argus analyst Stephen Biggar kept his Buy rating and $62 price target on Morgan Stanley after its Q2 earnings beat, saying the results were bolstered by strength across investment banking, trading, and asset management. The analyst also notes the pretax margin in the Morgan Stanley the wealth management segment was 27%, which is on the high end of the recently raised guidance, while its ROE of 14.9% was above the 10%-13% forecast range for 2018-19. Biggar further contends that the share price weakness in Morgan Stanley since mid-May is unwarranted by its fundamentals and believes investors are offered an "attractive entry point" for the stock.
07/19/18
07/19/18
UPGRADE

Market Perform
Morgan Stanley upgraded to Market Perform on more balanced risk/reward at Bernstein
As previously reported, Bernstein analyst Christian Bolu upgraded Morgan Stanley to Market Perform from Underperform saying that while he still sees some risks, his concerns are now better reflected in the stock given price underperformance over recent months. Wealth management still a risk, but now a better understood risk, he contends.
CTL CenturyLink
$22.90

(0.00%)

09/25/18
OPCO
09/25/18
NO CHANGE
Target $24
OPCO
Outperform
CenturyLink CFO departure raises concerns, says Oppenheimer
Oppenheimer analyst Timothy Horan notes CenturyLink (CTL) has announced that CFO Sunit Patel will depart as of September 28th to join T-Mobile (TMUS) to lead the Sprint (S)/T-Mobile merger and integration efforts. The analyst expects weakness in CenturyLink's stock, as investors will likely be concerned with synergy realization after Patel's departure. While Horan says his departure is disappointing, he believes CenturyLink has a deep management bench, and Jeff Storey, CEO, will continue to be the driving force behind restructuring and expense reductions at the company. He reiterates an Outperform rating and $24 price target on the shares.
07/18/18
07/18/18
DOWNGRADE
Target $17

Market Perform
Adtran downgraded to Market Perform after earnings at Northland
As previously reported, Northland analyst Tim Savageaux downgraded Adtran (ADTN) to Market Perform from Outperform following the company's Q2 report and Q3 revenue guidance that met consensus, stating that he views the shares as fairly valued given that he believes the earnings power needed to support a higher share price is "still a ways off." While Adtran is "slowly but clearly diversifying away" from CenturyLink (CTL), Savageaux has lowered expectations for any snap-back at CenturyLink and sees slower than expected progress at other U.S. Tier 1 telecom companies, he tells investors. The analyst, who reduced his estimates for 2019, cut his price target on Adtran shares to $17 from $20.
08/22/18
MOFT
08/22/18
DOWNGRADE
Target $19
MOFT
Sell
CenturyLink downgraded to Sell from Neutral at MoffettNathanson
MoffettNathanson analyst Nicholas Del Deo downgraded CenturyLink to Sell with a $19 price target. The shares closed yesterday up 13c to $23.98.
08/16/18
RBCM
08/16/18
NO CHANGE
Target $27
RBCM
Outperform
CenturyLink price target raised to $27 from $22 at RBC Capital
RBC Capital analyst Jonathan Atkin raised his price target on CenturyLink to $27 and kept his Outperform rating after its "solid" Q2 results and increased FY18 guidance on "stronger-than-expected synergy realization and benefits from portfolio rationalization". The analyst believes that the company's dividend yield is also safe and its operating expense synergy targets are "beatable". Atkin further notes that although CenturyLink's consumer business is "challenged", it only constitutes about 25% of its combined revenue, and its recent Level 3 Communications transaction helps its "pivot to the enterprise business" with "better underlying economics".
P Pandora
$8.98

(0.00%)

09/25/18
RBCM
09/25/18
NO CHANGE
Target $10
RBCM
Outperform
Competing big for Pandora 'unlikely', says RBC Capital
RBC Capital analyst Mark Mahaney kept his Outperform rating and $10 price target on Pandora (P) after yesterday's announcement of a pending acquisition by Sirius (SIRI). The analyst believes that this is a "logical strategic step" based on the potential synergies between the two, with the first having a very strong in-home presence and the latter a very strong in-car presence. Mahaney also sees the $10.14 per share acquisition price as very reasonable and consistent with his own price target derived from 1.5-times multiple of forward price to sales. The analyst further notes that a competing bid from potential other acquirers like Spotify (SPOT), Apple (AAPL), Google (GOOGL), and Amazon (AMZN) is "reasonable unlikely at this point".
09/25/18
RHCO
09/25/18
DOWNGRADE
Target $9.5
RHCO
Hold
Pandora downgraded to Hold from Buy at SunTrust
SunTrust analyst Matthew Thornton downgraded Pandora (P) to Hold from Buy and raised his price target to $9.50 from $8.50 after yesterday's announcement of an acquisition by Sirius XM (SIRI). The analyst says the deal makes sense strategically to merge its "free ad-supported and mobile/digital capabilities" with the latter's position in subscription, in-auto, and non-music content, but also contends that its valuation is "underwhelming" at just 18% premium to Friday's close. Thornton believes that another suitor, such as Spotify (SPOT), may emerge during the go-shop period.
09/25/18
RAJA
09/25/18
DOWNGRADE
RAJA
Market Perform
Pandora downgraded to Market Perform from Strong Buy at Raymond James
Raymond James analyst Justin Patterson downgraded Pandora (P) to Market Perform after the company agreed to be acquired by Sirius XM (SIRI). Patterson said there is little likelihood of a second bid emerging, but thinks shareholders will push back and Sirius XM will have to "sweeten the deal."
09/25/18
RHCO
09/25/18
DOWNGRADE
RHCO
Hold
Pandora downgraded to Hold from Buy at SunTrust
SQ Square
$86.06

(0.00%)

09/21/18
EVER
09/21/18
NO CHANGE
Target $101
EVER
Outperform
Square price target raised to $101 from $76 at Evercore ISI
Evercore ISI analyst Rayna Kumar raised her price target on Square to $101 and kept her Outperform rating citing the findings of her analysis of Square Cash App monetization. The analyst notes that the last two years saw the company launch new product features for the app including "Instant Deposit, the Square Cash Card, Bitcoin trading, and its reward program Boost", becoming a likely "material driver to both revenue and earnings over time". Kumar expects the app to contribute up to 16c to Square's FY20 EPS, 30c to FY21 EPS, and 40c in FY22 EPS, stating that the company's monetization strategy is in the "early innings".
09/25/18
JEFF
09/25/18
NO CHANGE
Target $88
JEFF
Hold
Square price target raised to $88 from $63 at Jefferies
Jefferies analyst John Hecht raised his price target for Square to $88 after taking a detailed look at the company's non-payments businesses. The analyst, however, keeps a Hold rating on the shares. Various sum-of-the-parts analyses points to current premium valuations for each segment, suggesting "strong growth and successful execution is likely priced-in," Hecht tells investors in a research note. While Square's Subscription & Services products are "no doubt well positioned," the stock's valuation remains full, Hecht contends.
09/25/18
NOMU
09/25/18
NO CHANGE
Target $125
NOMU
Buy
Square price target raised to $125 from $86 at Nomura Instinet
Nomura Instinet analyst Dan Dolev raised his price target for Square (SQ) to $125 from $86 and keeps a Buy rating on the shares. The stock closed yesterday up 75c to $86.04. The analyst's analysis of Square's fundamentals indicates "buoyant" gross payment volume, revenue and marketing efficacy trends. The company's "fully cohesive solutions and rapid rate of innovation" suggest that it is en route to disrupt the global payments ecosystem, Dolev tells investors in a research note titled "Improving Momentum Means $125 Is Within Reach." He believes this is similar to the FANG stocks, or Facebook (FB), Amazon.com (AMZN), Netflix (NFLX) and Google (GOOG, GOOGL), that have "disrupted traditional markets with massive" global total addressable markets. Further, Dolev believes shares of Square are not too expensive when taking into account its "stellar" 45% expected three-year annual revenue growth, which he thinks "makes it screen more attractively than many payment peers and FANG stocks."
09/20/18
STFL
09/20/18
NO CHANGE
Target $100
STFL
Buy
Square price target raised to $100 from $76 at Stifel
Stifel analyst Scott Devitt said he expects continued momentum from larger sellers as Square's retail ecosystem keeps evolving and he thinks the company's partnership efforts are expanding its reach and potential for cross- and up-selling. Devitt raised his intermediate and long-term revenue forecasts for Square and increased his price target on the shares to $100 from $76. He maintains a Buy rating on Square shares.

TODAY'S FREE FLY STORIES

UBER

Uber

$41.40

0.94 (2.32%)

17:49
05/24/19
05/24
17:49
05/24/19
17:49
Hot Stocks
Uber board director Ryan Graves intends to resign »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

APTO

Aptose Biosciences

$2.01

0.03 (1.52%)

17:46
05/24/19
05/24
17:46
05/24/19
17:46
Syndicate
Aptose Biosciences files for $40M at-the-market common stock offering »

Piper Jaffray and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

TRNX

Taronis Technologies

$0.48

0.004 (0.84%)

17:26
05/24/19
05/24
17:26
05/24/19
17:26
Syndicate
Breaking Syndicate news story on Taronis Technologies »

Taronis Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:25
05/24/19
05/24
17:25
05/24/19
17:25
Hot Stocks
U.S. Energy discloses Nasdaq notice regarding delayed 10-Q filing »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

17:22
05/24/19
05/24
17:22
05/24/19
17:22
Periodicals
Apple sued over allegedly selling users' iTunes data, Bloomberg says »

Apple is being sued by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SPCB

SuperCom

$1.17

-0.005 (-0.43%)

17:21
05/24/19
05/24
17:21
05/24/19
17:21
Hot Stocks
SuperCom discloses Nasdaq notice regarding delayed 20-F filing »

SuperCom received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:20
05/24/19
05/24
17:20
05/24/19
17:20
Hot Stocks
U.S. Energy receives noncompliance notice from Nasdaq »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:18
05/24/19
05/24
17:18
05/24/19
17:18
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:17
05/24/19
05/24
17:17
05/24/19
17:17
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$87.49

3.03 (3.59%)

, QGEN

Qiagen

$38.22

-0.255 (-0.66%)

16:57
05/24/19
05/24
16:57
05/24/19
16:57
Hot Stocks
Qiagen launches diagnostic for PIK3CA biomarkers in breast cancer »

Qiagen (QGEN) announced…

NVS

Novartis

$87.49

3.03 (3.59%)

QGEN

Qiagen

$38.22

-0.255 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 31

    May

  • 20

    Jun

  • 06

    Aug

AVH

Avianca

$3.96

0.91 (29.84%)

16:56
05/24/19
05/24
16:56
05/24/19
16:56
Periodicals
ANAC suspends flights, operations of Avianca Brasil, Reuters reports »

Brazil's ANAC said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

16:53
05/24/19
05/24
16:53
05/24/19
16:53
Periodicals
Apple acquires startup Tueo Health, CNBC reports »

Apple has bought Tueo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SHSP

SharpSpring

$16.37

-0.24 (-1.44%)

16:52
05/24/19
05/24
16:52
05/24/19
16:52
Syndicate
Breaking Syndicate news story on SharpSpring »

SharpSpring files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

CREG

China Recycling Energy

$0.48

0.005 (1.05%)

16:41
05/24/19
05/24
16:41
05/24/19
16:41
Syndicate
Breaking Syndicate news story on China Recycling Energy »

China Recycling Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FENC

Fennec

$3.88

(0.00%)

16:36
05/24/19
05/24
16:36
05/24/19
16:36
Conference/Events
Fennec management to meet with Wedbush »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 18

    Jun

TD

Toronto-Dominion

$56.66

0.65 (1.16%)

16:35
05/24/19
05/24
16:35
05/24/19
16:35
Syndicate
Breaking Syndicate news story on Toronto-Dominion »

Toronto-Dominion files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
05/24/19
05/24
16:30
05/24/19
16:30
Options
Preliminary option volume of 15.7M today »

Preliminary option volume…

CBUS

Cibus

$0.00

(0.00%)

16:25
05/24/19
05/24
16:25
05/24/19
16:25
Syndicate
Cibus requests withdrawal of registration statement »

The company's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$355.14

4.57 (1.30%)

16:23
05/24/19
05/24
16:23
05/24/19
16:23
Periodicals
Boeing 737 MAX return delayed by FAA expanding review, WSJ reports »

A review of Boeing's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

FB

Facebook

$181.03

0.14 (0.08%)

, BA

Boeing

$355.14

4.57 (1.30%)

16:20
05/24/19
05/24
16:20
05/24/19
16:20
On The Fly
Fly Intel: Wall Street's top stories for Friday »

U.S. stocks, which had a…

FB

Facebook

$181.03

0.14 (0.08%)

BA

Boeing

$355.14

4.57 (1.30%)

UAL

United Continental

$80.77

-0.14 (-0.17%)

SMI

SMIC

$5.23

-0.26 (-4.74%)

HPQ

HP Inc.

$20.03

0.835 (4.35%)

HPE

HP Enterprise

$14.36

0.03 (0.21%)

NVS

Novartis

$87.49

3.03 (3.59%)

CNC

Centene

$56.84

1.39 (2.51%)

WCG

WellCare

$275.45

0.99 (0.36%)

TSS

TSYS

$113.42

13.81 (13.86%)

GPN

Global Payments

$153.42

5.45 (3.68%)

HIBB

Hibbett Sports

$23.91

4.07 (20.51%)

DVAX

Dynavax

$5.77

-0.59 (-9.28%)

FL

Foot Locker

$44.39

-8.455 (-16.00%)

SPLK

Splunk

$119.13

-9.55 (-7.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 24

    May

  • 29

    May

  • 30

    May

  • 30

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 07

    Jun

  • 08

    Jun

  • 09

    Jun

  • 10

    Jun

  • 13

    Jun

  • 14

    Jun

  • 24

    Jun

  • 24

    Jun

  • 09

    Jul

  • 09

    Jul

  • 23

    Jul

  • 13

    Nov

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
05/24/19
05/24
16:20
05/24/19
16:20
Options
Closing CBOE SPX and VIX Index summary for May 24th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
05/24/19
05/24
16:17
05/24/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
05/24/19
05/24
16:16
05/24/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHE

Regional Health Properties

$2.06

0.09 (4.57%)

16:15
05/24/19
05/24
16:15
05/24/19
16:15
Hot Stocks
Regional Health Properties receives NYSE notice over late Form 10-Q filing »

Regional Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBIO

Translate Bio

$9.12

-0.09 (-0.98%)

16:14
05/24/19
05/24
16:14
05/24/19
16:14
Syndicate
Breaking Syndicate news story on Translate Bio »

Translate Bio files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.